Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic DiseaseModifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

被引：0
|
作者：
Gottlieb, Alice [1 ]
Husni, Elaine [2 ]
Shuler, Catherine [3 ]
Burge, Russel [3 ]
Lin, Chen-Yen [3 ]
Lee, Chin [3 ]
Gladman, Dafna [4 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2017年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
175
引用
收藏
页码：924 / 925
页数：2
相关论文
共 50 条
  • [21] SECUKINUMAB IMPROVES PHYSICAL FUNCTION, QUALITY OF LIFE, FATIGUE AND WORK PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN FUTURE 2, A PHASE 3 TRIAL
    Rahman, P.
    Strand, V.
    McInnes, I. B.
    Marzo-Ortega, H.
    Dokoupilova, E.
    Churchill, M.
    Kandala, S.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 356 - 356
  • [22] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [23] The Effect of Guselkumab on Work Productivity in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Peterson, Steven
    Agarwal, Prasheen
    Yang, Feifei
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Shiff, Natalie J.
    Zhou, Bei
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4613 - 4631
  • [24] Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaiVe Subjects with Active Psoriatic Arthritis
    Mease, Philip J.
    Gladman, Dafna D.
    Davenport, Eric K.
    Zhou, Xiaolei
    Guerette, Benoit
    Teng, Lichen
    Kaura, Satyin
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [25] Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis
    Mease, P.
    Gladman, D.
    Davenport, E.
    Zhou, X.
    Guerette, B.
    Teng, L.
    Kaura, S.
    Nash, P.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 34 - 35
  • [26] IXEKIZUMAB IMPROVES NAIL AND SKIN LESIONS THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS
    Merola, J. F.
    Rich, P.
    Dutz, J. P.
    Adams, D.
    Kerr, L.
    Kristensen, L. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 374 - 375
  • [27] IMPROVEMENTS IN WORK PRODUCTIVITY WITH UP TO 104 WEEKS OF APREMILAST MONOTHERAPY: RESULTS FROM A PHASE 3B, RANDOMISED, CONTROLLED STUDY IN BIOLOGIC-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, P. J.
    Gladman, D. D.
    Davenport, E. K.
    Zhou, X.
    Guerette, B.
    Teng, L.
    Kaura, S.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1598 - 1598
  • [28] IMPROVEMENTS IN WORK PRODUCTIVITY WITH UP TO 104 WEEKS OF APREMILAST MONOTHERAPY: RESULTS FROM A PHASE 3B, RANDOMIZED, CONTROLLED STUDY IN BIOLOGIC-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, Philip J.
    Gladman, Dafna D.
    Davenport, Eric K.
    Zhou, Xiaolei
    Guerette, Benoit
    Teng, Lichen
    Kaura, Satyin
    Nash, Peter
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 14 - 14
  • [29] Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors
    Merola, Joseph
    Rich, Phoebe
    Dutz, Jan
    Adams, David H.
    Kerr, Lisa
    Kristensen, Lars
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB172 - AB172
  • [30] Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Gottlieb, Alice B.
    Strand, Vibeke
    Kishimoto, Mitsumasa
    Mease, Philip
    Thaci, Diamant
    Birt, Julie
    Lee, Chin H.
    Shuler, Catherine L.
    Lin, Chen-Yen
    Gladman, Dafna D.
    RHEUMATOLOGY, 2018, 57 (10) : 1777 - 1788
12345